Published in Pathol Res Pract on March 01, 1991
Fibrous dysplasia with cartilaginous differentiation ("fibrocartilaginous dysplasia"): a review, with an illustrative case followed for 18 years. Skeletal Radiol (2003) 1.19
Fibrocartilaginous mesenchymoma of the spine in a child: a case report. Childs Nerv Syst (2010) 0.85
Fibrocartilagenous mesenchymoma of bone: the youngest reported case in a patient aged 1 year and 7 months. J Clin Pathol (2005) 0.85
Accumulation of m-iodobenzylguanidine by neuroblastoma cells results from independent uptake and storage mechanisms. Cancer Res (1991) 1.08
A combined evaluation of biochemical and morphological changes during human neuroblastoma cell differentiation. Cell Mol Neurobiol (1992) 0.98
Effects of gamma-interferon on the growth, morphology, and membrane and cytoskeletal proteins expression of Lan-1 cells. Exp Cell Res (1989) 0.89
Induction of monocyte-macrophage differentiation in a new diploid line of human hematopoietic cells (CM-S) by phorbol esters. Cancer Res (1982) 0.88
gamma-Interferon increases metaiodobenzylguanidine incorporation and retention in human neuroblastoma cells. Cancer Res (1992) 0.87
T cells from lymphoepithelial thymoma produce a biochemical variant of IL-2. Lymphokine Res (1985) 0.86
Morphologic and phenotypic changes of human neuroblastoma cells in culture induced by cytosine arabinoside. Exp Cell Res (1989) 0.86
Uncoordinate induction and differential regulation of HLA class-I and class-II expression by gamma-interferon in differentiating human neuroblastoma cells. Int J Cancer (1993) 0.85
Angiogenic and angiostatic microenvironment in tumors--role of gangliosides. Acta Oncol (1997) 0.85
Evidence of loss of N-myc amplification during the establishment of a human neuroblastoma cell line. Int J Cancer (1990) 0.81
[Diminished in vitro colony forming capacity of bone marrow cells in a case of chromosome 8 trisomy (mosaicism): criteria for "high risk" pre-leukemia syndrome]. Boll Ist Sieroter Milan (1981) 0.81
Stimulation of receptor-coupled phospholipase A2 by interferon-gamma. FEBS Lett (1992) 0.81
Cytogenetic and molecular study of two human neuroblastoma cell lines. Cancer Genet Cytogenet (1988) 0.81
The combination of gamma-interferon and tumor necrosis factor causes a rapid and extensive differentiation of human neuroblastoma cells. Cancer Res (1992) 0.80
Lymphoblastoid cells transfected with c-myc: downregulation of EBV-lytic antigens and impaired response of autologous CD4+ T cells in vitro. Int J Cancer (1996) 0.80
N-myc amplification at chromosome band 1p32 in neuroblastoma cells as investigated by in situ hybridization. J Cancer Res Clin Oncol (1988) 0.79
Protein kinase C isoenzymes in human neuroblasts. Involvement of PKC epsilon in cell differentiation. FEBS Lett (1993) 0.79
Antiblastic treatment does not affect N-myc gene amplification in neuroblastoma. Anticancer Res (1987) 0.78
N-myc oncogene amplification in a patient with IV-S neuroblastoma. Am J Pediatr Hematol Oncol (1987) 0.78
Expression of multiple drug resistance gene, MDR1, and N-myc oncogene in an Italian population of human neuroblastoma patients. Anticancer Res (1990) 0.78
Retinoic acid inhibits phosphatidylinositol turnover only in RA-sensitive while not in RA-resistant human neuroblastoma cells. Biochem Biophys Res Commun (1989) 0.78
Pleomorphic (anaplastic) neuroblastoma in nude mice. Arch Pathol Lab Med (1991) 0.77
Interferon-gamma-stimulated and GTP-binding-proteins-mediated phospholipase A2 activation in human neuroblasts. Biochem J (1993) 0.77
Processing of human cord blood by three different procedures for red blood cell depletion and mononuclear cell recovery. Vox Sang (1999) 0.76
Cloning and sequencing of isoform-specific regions of human Ca2+-independent protein kinase C (PKC)-encoding genes. Gene (1994) 0.76
Wilms' tumor after treatment. Pediatr Pathol (1992) 0.76
Modulation of alpha 1 beta 1, alpha 2 beta 1 and alpha 3 beta 1 integrin heterodimers during human neuroblastoma cell differentiation. FEBS Lett (1993) 0.76
N-myc oncogene amplification and catecholamine metabolism in patients with neuroblastoma. Lancet (1987) 0.76
Gamma-interferon, retinoic acid, and cytosine arabinoside induce neuroblastoma differentiation by different mechanisms. Cell Mol Neurobiol (1991) 0.76
Cisplatin induces modulation of transferrin receptor during cellular differentiation in vitro. Cancer Chemother Pharmacol (1986) 0.75
N-myc oncogene amplification in a pediatric case of glioblastoma multiforme. Childs Nerv Syst (1991) 0.75
Cisplatin-induced erythroid differentiation in K562 cells: modulation of transferrin receptor. Boll Ist Sieroter Milan (1988) 0.75
Prognostic significance of N-myc amplification in neuroblastoma. Clin Chem (1990) 0.75
N-myc and MDR1 expression are mutually exclusive in NB tumors at onset. Prog Clin Biol Res (1991) 0.75
In vitro response to mitogens and antigens in elderly and post-cytotoxic patients can be modified by a new hypoxanthine derivative (PCF-39). Boll Ist Sieroter Milan (1987) 0.75
High-performance liquid chromatographic determination in human plasma of a new immunomodulatory agent with a peptidyl-hypoxanthine structure (RM 06). J Chromatogr (1990) 0.75
Retinol (vitamin A) and retinal-binding protein serum levels in children with cancer at onset. Nutrition (1997) 0.75
[Activation of cellular N-myc oncogene in neuroblastoma]. Clin Ter (1988) 0.75
T-gamma lymphocytes in a case of congenital hypoplastic anemia (Diamond-Blackfan syndrome). Haematologica (1981) 0.75
Effect of cytosine arabinoside on the growth and phenotypic expression of GI-ME-N, a new human neuroblastoma cell line. Prog Clin Biol Res (1988) 0.75
In vitro and in vivo immunomodulatory activity of an N-9 arginyl hypoxanthine derivative (PCF-39). Int J Immunopharmacol (1987) 0.75
Different regulation of mid-size neurofilament and N-myc mRNA expression during neuroblastoma cell differentiation induced by retinoic acid. Cell Mol Neurobiol (1990) 0.75
Molecular analysis of HLA class II antigens in bone marrow transplanted thalassemic patients. Haematologica (1992) 0.75
[New line of human neuroblastoma derived from bone marrow]. Pathologica (1987) 0.75
Purification to homogeneity and biochemical characterization of two suppressor factors from human malignant T-cells. Biochem Biophys Res Commun (1988) 0.75
[Amplification of the N-myc cellular oncogene in neuroblastoma. Relation to other tumor markers]. Boll Ist Sieroter Milan (1986) 0.75
Neuroblastoma cells circulate in peripheral blood. Pediatr Hematol Oncol (1989) 0.75
Infantile leukemia with a new chromosomal rearrangement involving 11q. Cancer Genet Cytogenet (1988) 0.75
Morphological and biochemical modifications during neuroblastoma cell differentiation. Cytotechnology (1991) 0.75
[Bacterial infectious complications in children with acute lymphoblastic leukemia in the induction phase]. Minerva Pediatr (1983) 0.75
A pediatric case of cystic lymphangioma of the spleen. J Comput Assist Tomogr (1981) 0.75
[Use of OKT3 monoclonal antibodies and anti-TAC for the quantitative evaluation of interleukin-2]. Boll Ist Sieroter Milan (1985) 0.75
EBNA-negative polyclonal B cells derived from a long-term culture of unclassified acute lymphoblastic leukemia: IL-2-like activity of culture's supernatant. Int J Cell Cloning (1986) 0.75
A human acute leukemia-derived T-cell line produces two inhibitor factors which suppress lymphocyte proliferation: characterization and purification of the molecules. Lymphokine Res (1988) 0.75
In vitro pharmacology of metaiodobenzylguanidine uptake, storage and release in human neuroblastoma cells. J Nucl Biol Med (1992) 0.75
Engineering viral promoters for gene transfer to human neuroblasts. Cell Mol Neurobiol (2000) 0.75
Cystic lymphangioma of the spleen. Report of CT scan findings. Pediatr Radiol (1982) 0.75
[Serum levels of IgG subclasses in critically ill premature infants treated with intravenous immunoglobulins]. Minerva Pediatr (1991) 0.75
[In vitro synthesis of interleukin 2 (IL-2) by T lymphocytes extracted from a lymphoepithelial thymoma. Purification and biochemical characterization]. Boll Ist Sieroter Milan (1985) 0.75
[Oncogenes and neoplasms in children: hemo-lymphoproliferative diseases. II]. Minerva Pediatr (1986) 0.75
Sensory neuropeptides (substance P) and 4-11 SP enhance human neutrophils chemiluminescence; the role of L-arginine. Int J Immunopharmacol (1986) 0.75
[Cystic lymphangioma of the spleen (author's transl)]. Pediatr Med Chir (1982) 0.75
Effect of a new peptidyl-hypoxanthine derivative on natural killer cells and antitumor activity. Cancer Detect Prev (1991) 0.75
Does N-myc amplification correlate with other prognostic factors in advanced neuroblastoma? Preliminary results. Pediatr Hematol Oncol (1986) 0.75
Phosphatidylinositol turnover is not a general regulator of neuroblastoma cell differentiation: comparison between two differentiating agents, retinoic acid and gamma-interferon. FEBS Lett (1989) 0.75
Analysis of CD4 gene expression in human fetal brain and neuroblasts. Cell Mol Neurobiol (1992) 0.75
[Oncogenes and neoplasms in children: solid tumors. I]. Minerva Pediatr (1986) 0.75
Resistant and relapsing neuroblastoma: improved response rate with a new multiagent regimen (OC-HDP) including high-dose cisplatinum. Med Pediatr Oncol (1987) 0.75
Congenital leukemia: persistent spontaneous regression in a patient with an acquired abnormal karyotype. Acta Haematol (1989) 0.75
Biopharmacokinetic evaluation of peptichemio (PTC) by reversed-phase high-performance liquid chromatography (HPLC): preliminary in vitro studies. Boll Ist Sieroter Milan (1987) 0.75
Bone-marrow T-lymphoid cells: a simple method for enriched specimen. Boll Ist Sieroter Milan (1979) 0.75